"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 2 | 1 | 3 |
| 1998 | 2 | 2 | 4 |
| 1999 | 0 | 3 | 3 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 10 | 7 | 17 |
| 2005 | 10 | 9 | 19 |
| 2006 | 11 | 9 | 20 |
| 2007 | 8 | 3 | 11 |
| 2008 | 6 | 5 | 11 |
| 2009 | 7 | 6 | 13 |
| 2010 | 2 | 3 | 5 |
| 2011 | 6 | 2 | 8 |
| 2012 | 7 | 5 | 12 |
| 2013 | 6 | 3 | 9 |
| 2014 | 9 | 4 | 13 |
| 2015 | 12 | 7 | 19 |
| 2016 | 15 | 12 | 27 |
| 2017 | 233 | 117 | 350 |
| 2018 | 200 | 129 | 329 |
| 2019 | 63 | 49 | 112 |
| 2020 | 46 | 69 | 115 |
| 2021 | 73 | 79 | 152 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. J Infect Dis. 2022 01 18; 225(2):352-354.
-
Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. JAMA Cardiol. 2021 12 01; 6(12):1451-1460.
-
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody. Emerg Microbes Infect. 2021 Dec; 10(1):1638-1648.
-
Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients. Pediatr Infect Dis J. 2021 12 01; 40(12):e507-e509.
-
Not All Monoclonal Antibodies for Coronavirus Disease 2019 Are Created Equal. J Infect Dis. 2021 10 28; 224(8):1275-1277.
-
Anti-SARS-CoV-2 Monoclonal Antibodies in Solid-organ Transplant Patients. Transplantation. 2021 10 01; 105(10):e146-e147.
-
COVID-19 acute respiratory distress syndrome: A simulation study of the effects of combination therapy with tocilizumab and siltuximab. Br J Clin Pharmacol. 2022 03; 88(3):1043-1053.
-
Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLoS Pathog. 2021 09; 17(9):e1009885.
-
Surface Engineering of Graphene through Heterobifunctional Supramolecular-Covalent Scaffolds for Rapid COVID-19 Biomarker Detection. ACS Appl Mater Interfaces. 2021 Sep 15; 13(36):43696-43707.
-
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 09 02; 9:CD013825.